对伴有孤立性肝转移的结直肠癌患者进行综合基因组分析,以了解对癌症治疗的反应和耐药性 (COMPARISON)
This is a prospective study investigating the disease course of patients with colorectal cancer that have had their cancer spread to their liver. The aim of this study is find potential biomarkers for disease recurrence and therapeutic targets for prognostic information.
研究概览
详细说明
Colorectal cancer (CRC), the 2nd leading cause of cancer mortality, often has a pattern of targeting the liver during initial metastases. The Comprehensive Genomic Profiling of Colorectal Cancer Patients with Isolated Liver Metastases to Understand Response and Resistance to Cancer Therapy (COMPARISON) study aims to assess the disease course of CRC by collecting primary tumor and metastatic liver specimens following pre-operative chemotherapy. If relapse occurs following surgical resection of the liver, biopsies will also be done for molecular analysis. As a result, these samples can be analyzed for chemotherapy resistance mechanisms and therapeutic targets to determine potential clinical outcomes for this particular subset of CRC patients.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
British Columbia
-
Vancouver、British Columbia、加拿大、V5Z 4E6
- Vancouver Regional Cancer Centre
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 2M9
- Princess Margaret Cancer Centre
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
metastatic colorectal cancer, isolated liver metastases, at least 3 rounds of chemotherapy (FOLFOX or FOLFIRI +/- Bevacizumab) prior to planned liver resection
描述
Eligibility Criteria:
- Patients must have histologically confirmed CRC with isolated liver metastasis
- Patients must be planned for a hepatic metastasectomy
- Patients must have received at least 3 cycles of chemotherapy (FOLFOX or FOLFIRI with or without Bevacizumab) prior to the planned hepatic metastasectomy
- Primary tumor must be considered resectable with a plan for this to either occur concurrently with the liver resection or subsequent to this.
- If primary has already been resected before liver resection, archival tissue must be available for genomic analysis
- Patients must be 18yrs of age or older
- Ability to understand and willing to sign a written informed consent document
Exclusion Criteria:
- Patients with un-resectable or borderline resectable isolated liver metastases as judged by the multidisciplinary hepatobiliary tumor board at PM or BCCA after a course of pre-operative chemotherapy will be excluded
- Patients with evidence of possible metastatic disease at any sites outside the liver are not eligible
- Patients with any major co-morbidity or co-morbidities that will render liver resection very high risk in investigator's opinion
- Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
- Patients with a previous history of another primary cancer treated within 5 years of study entry are not eligible except those with basal cell or squamous cell carcinoma of the skin and intraepithelial neoplasia.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
|---|
|
Metastatic Colorectal Cancer with Isolated Liver Metastasis
Patients with advanced colorectal cancer with isolated liver metastasis. Primary cancer must be resectable (if no archival exists) and patient must be planned for liver resection with at least 3 cycles of chemotherapy prior to liver surgery. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
临床环境中与化疗耐药和肿瘤复发相关的特征基因组和表观遗传特征的利用率
大体时间:5年
|
5年
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
通过 NGS 平台上的连续 DNA 表征鉴定复发性肿瘤克隆的表观遗传图谱
大体时间:5年
|
5年
|
|
通过 NGS 平台上的连续 RNA 表征鉴定复发性肿瘤克隆的表观遗传图谱
大体时间:5年
|
5年
|
|
通过 MethylSeq 系列甲基化组分析鉴定复发性肿瘤克隆的 DNA 甲基化谱
大体时间:5年
|
5年
|
|
通过对血液样本进行超深度靶向 NGS 来无创检测 cfDNA 甲基化谱
大体时间:5年
|
5年
|
|
通过对血液样本执行 cfMeDIP-seq 来无创检测 cfDNA 甲基化谱
大体时间:5年
|
5年
|
合作者和调查者
调查人员
- 首席研究员:Kyaw Aung, MD、Princess Margaret Cancer Centre
- 首席研究员:Daniel Renouf, MD、British Columbia Cancer Agency
- 首席研究员:Lillian Siu, MD、Princess Margaret Cancer Centre
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.